https://www.thebodypro.com/author/polly-clayden

Latest by Polly Clayden

Low-Dose Boosted Atazanavir Non-Inferior to Standard Dose in LASA Study Img
IAS (International AIDS Society) Conference

Low-Dose Boosted Atazanavir Non-Inferior to Standard Dose in LASA Study

Atazanvir/ritonavir at 200/100 mg was found to be non-inferior to atazanvir/ritonavir at 300/100 mg, according to study results presented at IAS 2015.

Dispersible Tablet Formulation of Dolutegravir Bioequivalent to the Granule Formulation Img
IAS (International AIDS Society) Conference

Dispersible Tablet Formulation of Dolutegravir Bioequivalent to the Granule Formulation

A dispersible tablet formulation of dolutegravir (Tivicay, DTG) has been developed as an alternative to the granule formulation for infants and young children. Pharmacokinetic data presented at IAS 2015 showed the tablet and granule formulations are ...

Tribute to Bob Munk: Long-Time HIV-Positive U.S. Treatment Activist and Educator Img
IAS (International AIDS Society) Conference

Tribute to Bob Munk: Long-Time HIV-Positive U.S. Treatment Activist and Educator

It was with great sadness that in the week before IAS 2015 we learned of the death of Robert Munk, a long-time U.S. activist, friend and colleague.

WHO 2015 Guidelines to Recommend Treatment for All HIV-Positive People Img
IAS (International AIDS Society) Conference

WHO 2015 Guidelines to Recommend Treatment for All HIV-Positive People

Gottfried Hirnschall, Director of HIV Department at World Health Organization (WHO), provided a "sneak preview" of the in-the-process-of-being-updated 2015 consolidated guidelines.

Adolescents at Increased Risk of Vertical Transmission and Poor Pregnancy Outcome in South Africa Img
News

Adolescents at Increased Risk of Vertical Transmission and Poor Pregnancy Outcome in South Africa

Adolescent pregnant women had an increased risk of vertical transmission of HIV and poorer maternal and infant outcomes, compared to non-adolescent women, in a high HIV prevalence district in South Africa.

Lopinavir/Ritonavir Pellets for Children Tentatively Approved by the FDA Img
News

Lopinavir/Ritonavir Pellets for Children Tentatively Approved by the FDA

On May 21, the U.S. Food and Drug Administration tentatively approved lopinavir/ritonavir 40/10-mg pellets for infants and young children less than 3 years old.

Pharmacokinetics in Pregnancy: Darunavir/Ritonavir and Etravirine Img
News

Pharmacokinetics in Pregnancy: Darunavir/Ritonavir and Etravirine

Two small studies presented at the 5th International Workshop on HIV & Women evaluated the pharmacokinetics of darunavir/ritonavir (DRV/r) and etravirine (ETV) respectively in pregnancy. In both studies drug exposure was altered -- lower for DRV and ...

Pregnancy Rates Among Women Using Antiretroviral Therapy and Hormonal Contraceptives in Kenya Img
Kenya

Pregnancy Rates Among Women Using Antiretroviral Therapy and Hormonal Contraceptives in Kenya

Incident pregnancy rates in HIV-positive women using the subdermal hormonal implant with efavirenz-based antiretroviral therapy were 2.6 times higher than in women using nevirapine-based antiretroviral therapy, according to a study conducted in Weste...

Gender Difference in Virological Response to Antiretroviral Therapy Img

Gender Difference in Virological Response to Antiretroviral Therapy

A study conducted in the U.K. found that although rates of virological failure are low in people starting first-line antiretroviral therapy, women and men who have sex with women (MSW) remain more likely to experience this than men who have sex with ...

HIV and Pregnancy Audit 2013 to 2014 Img
Women

HIV and Pregnancy Audit 2013 to 2014

Most initial treatment regimens were compliant with BHIVA guidelines, with treatment started in nearly 80% of cases. However, many women started treatment late and this was mostly not explained by late booking.